Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Hold” by Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has earned an average rating of “Hold” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $9.80.

ANRO has been the topic of a number of recent research reports. Chardan Capital initiated coverage on shares of Alto Neuroscience in a research note on Monday, September 29th. They set a “buy” rating and a $15.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Alto Neuroscience in a research note on Monday, August 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Saturday, September 27th.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $6.55 on Tuesday. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $15.04. The company has a 50-day simple moving average of $3.74 and a 200 day simple moving average of $2.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43. The company has a market capitalization of $177.35 million, a PE ratio of -2.74 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). On average, research analysts predict that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

A number of institutional investors have recently modified their holdings of ANRO. Armistice Capital LLC lifted its stake in shares of Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock valued at $3,456,000 after buying an additional 950,000 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in Alto Neuroscience during the second quarter valued at approximately $613,000. AWM Investment Company Inc. grew its stake in Alto Neuroscience by 31.1% during the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock valued at $1,948,000 after acquiring an additional 214,153 shares in the last quarter. Nuveen LLC purchased a new position in Alto Neuroscience during the first quarter valued at approximately $302,000. Finally, Jane Street Group LLC purchased a new position in Alto Neuroscience during the second quarter valued at approximately $240,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.